Gilenya Cuts in Fall 2014

Discussion in 'Novartis' started by Anonymous, Mar 31, 2014 at 1:05 AM.

Tags: Add Tags
  1. Anonymous

    Anonymous Guest

    Cutting down to single covered territories in the fall. Biogen keeping product from blowing It out. No need or dual covered territories.
     

  2. Anonymous

    Anonymous Guest

    First of all not all territories have 2 reps dude. Second Biogen has 3 reps with smaller territories. Third Gilenya does over 1 billion with 100 reps max. Sorry but no cuts coming.
     
  3. Anonymous

    Anonymous Guest

    If your religated to last line therapy based upon risk/benefit/work from the physician/patient perspective, why wouldn't you restructure?
     
  4. Anonymous

    Anonymous Guest

    True. This was another Novartis product that was poorly launched and wll never recover. Biogen needs the reps cause they are blowing it out. Mark my words, Novartis will move to exclusively singled covered territories in 6 months. Just wait and see.
     
  5. Anonymous

    Anonymous Guest

    Troll quit posting on here. Gilenya is the one product that is making Novartis a lot of $$ and there are a couple new possible indications coming later this year. And you think they will cut an already small salesforce? Use your head. The only ones getting cut this year are Gen Meds oh and maybe Hospital. Quit stirring the pot loser
     
  6. Anonymous

    Anonymous Guest

    Classic defense mechanism. Ignore reality and the unstable history of Novartis. Long around you fool. MS is only Novartis division with Pods. Those days are numbered and that's fact. Just watch
     
  7. Anonymous

    Anonymous Guest

    Biogen's Tecfidera is now the top oral MS therapy and is blunting Gilenya's growth. It also is cheaper in cost, which Biogen can leverage along with Tysabri with payers.
     
  8. Anonymous

    Anonymous Guest

    Hmmm no dumb ass Onc also has 2 per territory some more. Quit spreading fear. So using your logic the MS team will have 50 reps just in time when we get 2 additional indications and generate over a billion? Use your head for once!
     
  9. Anonymous

    Anonymous Guest

    Not to mention Biogen does it have monitoring baggage like Gilenya.
     
  10. Anonymous

    Anonymous Guest

    I agree with #8, this guy is just trying to stir the pot. Gilenya, for all its troubles, is the one franchise that is doing very well in terms of ROI for NVS. Over a billion dollars and soon to be more if those new indications are approved. Yes Tec is kicking butt but a billion is still a billion.
     
  11. Anonymous

    Anonymous Guest

    Yes, but now that there is competition, the ability to grow that "nut" is diminished. New Rx's will be flat or decline. Only price increases will drive revenue, but also further add to the cost wedge.
     
  12. Anonymous

    Anonymous Guest

    Would not be at all surprised by cuts to one rep per territory. Access is limited and offices don't want or need two reps. Sales would not suffer at all if one good rep per territory. Just because some competitor has a bloated sales force doesn't mean that's the right thing to do. In fact if I was an office manager I'd limit access to no more than one or two rep visits per month total (counting all positions/titles from any one product line). The healthcare business is just too busy now. Overworked docs, overworked staff trying to see too many patients in too little time, day after day, week after week with industry people who have their own agendas, which has more to do with sales quotas than patient care delivery.
    Try the view from inside the reception window sometime and in three days you'll agree with this assessment.
     
  13. Anonymous

    Anonymous Guest

    Ok either you nimrods are all independently wealthy or just plain suicidal. Why are you wishing for MS to cuts it's already small salesforce in half? And for those with a brain why the f$&@ would NVS do that in the eve of 2 new indications with over 2 billion in potential?
     
  14. Anonymous

    Anonymous Guest

    Open you eyes pal....... Love these clueless reps who don't see reality and think they are safe.
     
  15. Anonymous

    Anonymous Guest

    Okay.... Pal... Then explain in business language why this would make sense?? Again the info I have is we have 2 billion dollar indications coming up. And you think NVS will cut a 100 rep salesforce in half? Okay... What info do you have to retort this? And please don't just say well they should? Use business sense or logic please. Okay your turn
     
  16. Anonymous

    Anonymous Guest

    Good luck. If you have been in MS for anytime then you would no there is no magical new indication that will add 2 billion in sales. Gilenya will be fine but don't expect much upside as it does not exist.
     
  17. Anonymous

    Anonymous Guest

    Put your crack pipe down son. Look at the Pharma model that's been in place for last couple of years...... He'll look at what's happen under our eyes at Novartis in recent years. Open your eyes son, it's for your own good.
     
  18. Anonymous

    Anonymous Guest

    Yup just like I thought no real logic or substance. Yes model is changing but you didn't provide any substantitive proof buddy.
     
  19. Anonymous

    Anonymous Guest

    Meaning proof about MSBU. Quit spreading fears.
     
  20. Anonymous

    Anonymous Guest

    I don't know about reps but management will sure be cut. Not because there are too many, but because they messed up big time. The select few know they are on the hot seat and are sweating everyday. Doesn't matter if you have been around for 3 1/2 years or 18 years, management is just a number like reps. Any guesses who these people are?